CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 82 enrolled
Drug / intervention
ELX/TEZ/IVA +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04969224
NCT04969224Phase 3Completed
CompareCT.gov

A Phase 3b Open-label Study Evaluating the Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cough and Physical Activity in Cystic Fibrosis Subjects 12 Years of Age and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Vertex Pharmaceuticals Incorporated·interventional·Posted Jul 20, 2021·Updated Sep 24, 2025

In Brief

A Phase 3 clinical trial evaluating ELX/TEZ/IVA and IVA for Cystic Fibrosis. Completed, enrolled 82 participants across 19 sites in 4 countries.

Detailed Summary

This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesAustralia, Belgium, Canada, Spain
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedJul 20, 2021
Enrollment StartOct 12, 2021
Primary CompletionJul 26, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.0 years ago

Interventions

ELX/TEZ/IVAdrug

Fixed dose combination (FDC) tablet for oral administration.

IVAdrug

Tablet for oral administration.